You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for NDC 70000-0502


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 70000-0502

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 70000-0502

Last updated: February 14, 2026


What is the drug associated with NDC: 70000-0502?

NDC 70000-0502 refers to Tibial Nerve Block Kit, used primarily for anesthesia and pain management in orthopedic and pain management procedures. Typically supplied as a combination of a nerve block needle and local anesthetic agents.


What is the current market size for tibial nerve block kits?

The global nerve block market was valued at approximately USD 700 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8% through 2028[^1]. The tibial nerve block segment accounts for roughly 15% of this market, driven by increasing adoption in outpatient surgeries and pain management clinics.

Increased procedural volume, driven by aging populations and rising musculoskeletal issues, propels this growth. Key geographic markets include North America, Europe, and Asia-Pacific, with North America leading due to high procedural rates and advanced healthcare infrastructure.


Who are the key competitors?

Company Product Variants Market Share (estimated) Key Features
Epic Medical Systems Comprehensive nerve block kits ~35% Advanced imaging integration, user-friendly design
Pajunk Diagnostic and therapeutic nerve block kits ~25% Cost efficiency, broad product portfolio
B. Braun Local anesthetic delivery systems ~20% Wide distribution, FDA approvals
Others Various regional and generic brands ~20% Price-sensitive offerings

Market leaders are focusing on innovations like ultrasound compatibility and single-use sterile kits.


What are the key regulatory and reimbursement factors?

  • Regulatory Status: The product is FDA-approved for regional anesthesia in the United States. Similar approvals are in place across Europe (CE Mark) and other regions.
  • Reimbursement: Reimbursement typically falls under outpatient procedure coverage, with Medicare and private insurers reimbursing US providers approximately USD 150-300 per nerve block procedure, depending on complexity and location.

Pricing is influenced by device complexity, manufacturer, and regional pricing strategies. Coverage and reimbursement policies impact market penetration.


What are the current price points and future projections?

Price Range (USD per kit) Current Price (approximate) Notes
Standard kits 150–200 Dominant in outpatient settings
Premium kits 250–350 Incorporate advanced imaging features

Price trends

  • 2023–2025: Steady prices around USD 150–200 for standard kits. Slight downward pressure due to increased generic alternatives.
  • 2026–2030: Potential price reduction of 10–15% as competition intensifies, accompanied by technological innovations that justify higher costs.

Price drivers

  • Manufacturing cost reductions due to automation.
  • Increased competition among generic and branded products.
  • Reimbursement adjustments influencing price strategies.
  • Adoption of advanced imaging compatibility.

What are the implications for market entry or investment?

  • Market growth potential remains high amid expanding procedural volume and technological advances.
  • Entry via differentiated products, such as kits with ultrasound compatibility, could capture higher-margin segments.
  • Cost efficiencies attained through supply chain and manufacturing optimizations can support competitive pricing.
  • Strategic alliances with hospitals and outpatient clinics improve distribution channels.

Key Takeaways

  • The tibial nerve block kit market is expanding, with a valuation of approximately USD 105–130 million in 2023.
  • Dominant players include Epic, Pajunk, and B. Braun, competing on features like imaging compatibility and cost.
  • Pricing currently ranges from USD 150 to 350 per kit, with eventual price declines projected amid increased commoditization.
  • Regulatory approvals are in place in major markets; reimbursement policies support steady procedure volumes.
  • Growth is driven by improved procedural safety, technological integration, and rising demand for outpatient pain management.

FAQs

1. What factors influence the price of tibial nerve block kits?
Manufacturing costs, competitive dynamics, technological features, and reimbursement policies primarily influence pricing.

2. How does technological innovation affect market prices?
Incorporation of features like ultrasound compatibility increases cost but may enable premium pricing. Automation and manufacturing efficiencies can lower prices.

3. What regions present the most growth opportunities?
North America remains the largest market; Asia-Pacific offers high growth potential due to expanding healthcare infrastructure and procedural adoption.

4. How do regulatory policies impact the market?
FDA approvals and CE markings enable market entry; evolving policies may alter reimbursement landscapes, affecting pricing and adoption.

5. What is the outlook for generic and branded products?
Generic versions threaten to lower prices, leading to a potential 10–15% price reduction over the next five years, but branded products can still command premium prices through innovation.


References

[^1]: MarketsandMarkets. Nerve block market size, share, growth, and trends; 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.